New Cream for Plaque Psoriasis in Adults Approved
The FDA has approved a new topical medication for plaque psoriasis. This medication is a steroid-free option for patients who want a non-steroid alternative. Dermatologists can now prescribe this cream for patients suffering from plaque psoriasis.
Tapinarof Cream 1% is a steroid-free topical cream used to treat mild, moderate, or severe plaque psoriasis in adults. It is applied once daily.
Tapinarof is approved by the Food and Drug Administration (FDA). The trial results showed that the drug improved patients’ symptoms.
At the end of 12 weeks of treatment, 36% of participants from Psoarigin 1 and 40% of those from Psoarigina 2 reached the primary endpoint. Compared to 6% of the placebo group. Significant improvement from the baseline. Patients showed a 75% or greater improvement in the psoriasis area and severity index.
In addition, 73% of the study participants who achieve the primary outcome continue to soar 3, a 40-weeks extension study. During this period, the researchers discontinue treatments. The participants retain their physicians global assessment scores of 0 or 1 about 4 months. Mild to moderate adverse events include: ”
This drug may be effective for treating psoriasis, but there are some side effects. Folliculitis is an acne-like rash, and it could happen if you take this medication. There are also other possible side effects such as headache, nausea, diarrhea, dizziness, and abdominal pain.
Tapinarof is an effective treatment for eczema. It can be applied to any part of the body, including the face, neck, genitals, anus, and armpits.
Psoriasis is a skin disease that causes redness and thick patches of skin. Traditionally, steroids were used to treat this disease. However, these steroids cause side effects such as weight gain, high blood pressure, diabetes, and heart problems. Tapinarof is a new drug that works by reducing inflammation. This drug is applied topically and does not affect other parts of your body.
